- Home
- ZYME vs SKE Comparison
ZYME vs SKE Comparison
Compare ZYME & SKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- SKE
- Stock Information
- Founded
- ZYME 2003
- SKE 1979
- Country
- ZYME United States
- SKE Canada
- Employees
- ZYME 290
- SKE N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- SKE Precious Metals
- Sector
- ZYME Health Care
- SKE Basic Materials
- Exchange
- ZYME Nasdaq
- SKE Nasdaq
- Market Cap
- ZYME 956.0M
- SKE 997.4M
- IPO Year
- ZYME 2017
- SKE N/A
- Fundamental
- Price
- ZYME $13.88
- SKE $9.43
- Analyst Decision
- ZYME Buy
- SKE
- Analyst Count
- ZYME 6
- SKE 0
- Target Price
- ZYME $19.17
- SKE N/A
- AVG Volume (30 Days)
- ZYME 565.8K
- SKE 266.3K
- Earning Date
- ZYME 03-05-2025
- SKE 11-14-2024
- Dividend Yield
- ZYME N/A
- SKE N/A
- EPS Growth
- ZYME N/A
- SKE N/A
- EPS
- ZYME N/A
- SKE N/A
- Revenue
- ZYME $62,199,000.00
- SKE N/A
- Revenue This Year
- ZYME $21.53
- SKE N/A
- Revenue Next Year
- ZYME N/A
- SKE $50.00
- P/E Ratio
- ZYME N/A
- SKE N/A
- Revenue Growth
- ZYME N/A
- SKE N/A
- 52 Week Low
- ZYME $7.97
- SKE $3.29
- 52 Week High
- ZYME $17.70
- SKE $10.33
- Technical
- Relative Strength Index (RSI)
- ZYME 48.04
- SKE 53.14
- Support Level
- ZYME $12.80
- SKE $8.91
- Resistance Level
- ZYME $14.63
- SKE $10.23
- Average True Range (ATR)
- ZYME 0.85
- SKE 0.45
- MACD
- ZYME -0.04
- SKE 0.01
- Stochastic Oscillator
- ZYME 25.29
- SKE 51.22
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About SKE Skeena Resources Limited
Skeena Resources Ltd is a Canadian mining exploration company focused on developing prospective precious and base metal properties in the Golden Triangle of northwest British Columbia, Canada. The company's primary activity is the exploration and development of the past-producing Eskay Creek mine acquired from Barrick.